The in-vitro properties of ceftazidime.
Ceftazidime showed a high level of in-vitro antibacterial activity against the Enterobacteriaceae with geometric mean MICs of 0.07-0.5 mg/l and at least 90% of isolates sensitive to 8 mg/l. This cephalosporin was at least as active as gentamicin against gentamicin-sensitive Enterobacteriaceae and showed no significant reduction in activity against gentamicin-resistant strains. The activity of ceftazidime against Pseudomonas species was of special note with all the 204 isolates tested sensitive to 8 mg/l and was highly active against gentamicin-resistant strains. Activity against Staphylococcus aureus was moderate, whilst streptococci were highly susceptible. Activity against Bacteroides fragilis was moderate but a range of anaerobic bacilli and cocci were sensitive. Ceftazidime showed no significant inoculum effects, was rapidly bactericidal and as stable as cefoxitin to a wide range of cell-free beta-lactamases. The spectrum and activity of ceftazidime suggest that it may replace the aminoglycosides currently in clinical use.
Harper
P B
PB
Microbiology Division, Glaxo Group Research Ltd, Greenford, Middlesex, England.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002442:Ceftazidime / Q000378:metabolism / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002442:Ceftazidime; D001618:beta-Lactamases